RUFY3

Across TCGA pan-cancer cohorts, RUFY3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RUFY3 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RUFY3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RUFY3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where RUFY3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.660	0.320	.002	21	view →
LSCC	DFS	Tertile	III,IV	0.487	1.000	.008	13	view →
GBM	DFS	Quartile	All	0.249	0.514	.024	7	view →
LUAD	OS	Median	III,IV	0.376	0.868	.026	4	view →
CCRCC	DFS	Median	III,IV	0.452	0.695	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RUFY3–PDAC (DFS)

Open the PDAC breakdown →